Rituxan Hycela (rituximab) was granted approval by the Food and Drug Administration (FDA) for adult patients with previously untreated and r...
563
0Like
More focus is now being put on the needs of adolescents and young adults (AYA) with cancer. For example, a phase 2 trial is investigati...
388
0Like
According to updated findings from the core group of the phase 1 TRANSCEND study, treatment with JCAR017 showed a 59 percent complete respon...
453
0Like
Regardless of previous treatment with Adcetris (brentuximab vedotin), patients with relapsed or refractory Hodgkin lymphoma who had autologo...
496
0Like
There is currently no standard of care for patients with relapsed or refractory mantle cell lymphoma (MCL), but a recent phase 2 study prove...
404
0Like
Researchers are anticipating novel combinations to improve care in the treatment of mantle cell lymphoma (MCL) as the treatment paradigm con...
587
0Like
Axicabtagene ciloleucel (KTE-C19; axi-cel) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of tran...
448
0Like
There is currently no uniform procedure for patients with double-hit lymphoma (DHL) that prolongs benefit. Some patients receive autologous ...
248
0Like
Copanlisib was granted a priority review designation by the Food and Drug Administratioin (FDA) for the treatment of patients with relapsed/...
409
0Like
There were nearly identical response rates and toxicity with subcutaneous administration of Rituxan (rituximab) and IV administration of the...
252
0Like